Business Wire

GN Hearing Launches ReSound ENZO 3D™ and Beltone Boost Max™ – Bringing its New Hearing Care Experience to People with Severe to Profound Hearing Loss

Jaa

Today, GN Hearing announced the launch of ReSound ENZO 3D™, and the corresponding Beltone Boost Max™, which brings the renowned benefits of ReSound LiNX 3D™ and Beltone Trust™ to people with severe to profound hearing loss. Based on GN Hearing’s 5th generation 2.4 GHz wireless technology and GN Hearing’s 3rd generation binaural directionality, ReSound ENZO 3D has been proven to allow users to experience 60% more clarity of the sounds around them* and 60% better speech understanding in noise**.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170830005549/en/

Available in North America and all primary markets around the world to follow, ReSound ENZO 3D and B ...

Available in North America and all primary markets around the world to follow, ReSound ENZO 3D and Beltone Boost Max provide unmatched sound quality, efficient fitting, and groundbreaking comprehensive fine-tuning where ever you are, giving users with severe to profound hearing loss a new hearing care experience. (Photo: Business Wire)

Now available in North America and all primary markets around the world to follow, ReSound ENZO 3D provides unmatched sound quality, efficient fitting, and groundbreaking comprehensive fine-tuning where ever you are, giving users with severe to profound hearing loss a new hearing care experience.

Unmatched sound quality

With ReSound ENZO 3D and GN Hearing’s 3rd generation binaural directionality hearing aid users with severe to profound hearing loss will experience excellent sound quality and improved clarity in any environment. Regardless of their location, users of ReSound ENZO 3D can pick up more sounds and speech in any environment, whether they are in a noisy restaurant or on a windy hike.

Enhanced fitting experience

GN Hearing’s ReSound Smart Fit™ fitting software, developed together with audiologists, brings a more efficient and intuitive solution to the clinic, improving the fitting experience by simplifying the process where the hearing care professional fits and adjusts the hearing aid to the user. The efficient and intuitive wireless fitting will save time for both the user and the hearing care professional, giving hearing care professionals more time for valuable user counselling.

Hearing care wherever you are – whoever you are

ReSound ENZO 3D is the only hearing aid in the world with comprehensive remote fine-tuning capabilities for those with severe to profound hearing loss. Enabled by ReSound Assist, this groundbreaking new feature allows users to stay in touch with their hearing care professional wherever they are and whoever they are, receiving on-the-go hearing care and new settings securely via the cloud without having to schedule and travel for a clinic appointment. ReSound Assist is accessed via the recently launched app, ReSound Smart 3D™, (available on the App Store and Google Play), which also allows users to easily personalize and control their sound at any time on-the-go directly from a smartphone. Users can also stream phone calls and music from their smartphone to their ReSound ENZO 3D hearing aids.

ReSound ENZO 3D is the smallest and most powerful super power hearing aid available, and also a Made for iPhone Cochlear compatible bimodal hearing solution.

“At GN Hearing, we’re proud to bring the unrivalled benefits of ReSound LiNX 3D to those with severe to profound hearing loss with ReSound ENZO 3D, giving them a new hearing care experience. ReSound ENZO 3D is the most powerful hearing aid on the market with unmatched sound quality delivering more clarity and better speech understanding in noise. In addition, we offer the only comprehensive remote fine-tuning solution because we believe that everyone should be able to hear more than they ever thought possible, whoever they are and wherever they are. Our solutions are made for all,” says Anders Hedegaard, President and CEO at GN Hearing.

“I can hear the waves, I can hear the breeze. It’s a fantastic balance of sound. Everything has a lot more layers now to what I’m hearing. I’m not just hearing traffic – I am hearing layers of traffic. I’m hearing the difference between small cars, trucks and motorcycles, and I can hear things coming from different angles so I have got a lot of directionality,” says Tara Svensson, ReSound ENZO 3D user.

For more information please visit http://www.resound.com

*compared to binaural beamforming in hearing aids for severe-to-profound hearing loss (Effect of directional strategy on audibility of sounds in the environment for varying hearing loss severity. Jespersen C, Kirkwood B, Groth J., 2017).
**with Binaural Directionality III compared to omni directionality (Binaural Directionality III compared to omni directional, data on file)

About GN Hearing

People with hearing loss are at the heart of everything we do. ReSound, Beltone and Interton hearing aids help people feel more involved, connected and in control. In an ever-smarter world, we think big and challenge the norm so that we can transform lives through the power of sound.

GN Hearing is part of the GN Group – pioneering great sound from world-leading ReSound, Beltone and Interton hearing aids to Jabra office headsets and sports headphones. Founded in 1869, employing over 5,000 people, and listed on Nasdaq Copenhagen, GN makes life sound better.

Contact information

GN Hearing
Investor Relations
Peter Justesen, +45 4030 7879
pjustesen@gn.com
or
Media Relations
Lars Otto Andersen-Lange, +45 2484 8782
loalange@gn.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme